ABCL:NASDAQ
AbCellera Biologics Inc
$12.64
arrow_upward
+8.27%(+0.97) 1D
Sep 17, 3:21:36 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$12.15
High
$13.18
Low
$11.99
Mkt. cap
4.09B
Avg. vol.
8.23M
Volume
6.17M
52-wk high
$13.18
52-wk low
$2.74
EPS
-$0.54
Beta
1.32
Shares outstanding
324.05M
No. of employees
562
Open
$12.15
High
$13.18
Low
$11.99
Mkt. cap
4.09B
Avg. vol.
8.23M
Volume
6.17M
52-wk high
$13.18
52-wk low
$2.74
EPS
-$0.54
Beta
1.32
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
Investing.com
·
4 hours ago
Abcellera Biologics stock hits 52-week high at 12.58 USD
Stock Traders Daily
·
18 hours ago
How (ABCL) Movements Inform Risk Allocation Models
GuruFocus
·
22 hours ago
ABCL Looks 171.0% Overvalued on GF Valueâ„¢
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com